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Abstract 
 
Objective: To determine the prognostic value of pulmonary function test (PFT) trends at one and two years 
in interstitial lung disease associated with systemic sclerosis (SSc-ILD), (should we also  add the aim of 
defining optimal outcomes for clinical trials here at the start?). 
Methods: The prognostic significance of PFT trends at one year (n=162), and two years (n=140) was 
examined against 15 year survival.  PFT trends, expressed as continuous and categorical change in separate 
analyses, were examined against mortality in univariate and multivariate models. SSc-ILD was defined at 
presentation as limited or extensive using the UKRSA staging system.  
Results: At one year, PFT trends were predictive of mortality only in patients with extensive SSc-ILD: 
categorical FVC change, alone or in combination with categorical change in DLco,  had greater prognostic 
significance than continuous FVC change or trends in other PFT variables.  Taking into account both 
prognostic value and sensitivity to change, the optimal definition of progression for trial purposes was an 
FVC and DLco composite, consisting of  either an FVC decline from baseline>10% or an FVC decline of 5-
9%  in association with a DLco decline of >15%. At two years, DLco (? Or have you said gas transfer 
because you want to include both DLco and Kco?))  trends (is this both categorical and continuous?) had the 
greatest prognostic significance, in the whole cohort and in limited disease.  However, in extensive disease, 
the composite end-point defined above was the strongest prognostic determinant.  Larger changes were 
required in the FVC/DLco ratio than in Kco to achieve prognostic significance.      
Conclusion:  Our findings provide support for routine spirometric and gas transfer monitoring in SSc-ILD, 
based on linkages to long-term outcome, with further evaluation of a composite FVC and DLco end-point 
warranted for trial purposes.    
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Introduction 
 
At presentation, the broad approach to prognostic evaluation differs little between systemic sclerosis-
associated interstitial lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF).  In both diseases, 
mortality is linked to baseline disease severity, variably quantified using pulmonary function tests and 
HRCT (1-5).  However, prognostic evaluation in IPF is more nuanced than in SSc-ILD in one important 
regard.  It has been demonstrated in a large number of IPF studies that serial decline in forced vital capacity 
(FVC) over six to 12 months is a powerful predictor of mortality (6-15).Based on these findings, FVC is 
now universally regarded as central to routine monitoring in IPF (16).  Furthermore, links between short 
term FVC change and mortality provide support for the choice of FVC as the primary end-point in current 
IPF trials (17;18). . 
 
In SSc-ILD, limited (19)  data currently exist examining the relationship between short-term pulmonary 
function trends and intermediate to long-term survival.  Although conventional pulmonary function 
thresholds have been explored for clinical practice (19), little is known about the optimal measure for  use in 
clinical trials. Monitoring strategies in clinical practice and the choice of FVC as a primary end-point in 
treatment trials in SSc-ILD have largely been  based upon IPF studies. However, important caveats in 
extrapolating from IPF data include the fact that SScILD is less progressive than IPF (potentially influencing 
the optimal expression of FVC trends in prognostic evaluation) and the existence of disproportionate 
pulmonary vasculopathy in many SSc-ILD patients (20). 
 
We have evaluated relationships in SSc-ILD between pulmonary function trends at one year and at two 
years against 15 year survival in a large cohort with definitive follow-up information.  Our findings have 
implications both for routine clinical monitoring and future study design in SSc-ILD.  
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Methods 
 
Patients 
Data were reviewed from 215 SSc-ILD patients from a previously published cohort (in which baseline 
variables were examined against outcome)  (3).  Exclusion criteria comprised of: 1) death within nine 
months of follow up (n=15); no serial lung function measurements within the first 12 months [because of a 
shared model of care (n=38)].  The remaining 162 patients made up the study population. The study cohort 
of 162 patients was compared to the 38 excluded patients with more than nine months of follow up in order 
to exclude major selection bias.  
 
Clinical data 
Smoking status was defined as never, former (>1 cigarette/day for >1 year) or current smoking. Treatment 
was defined as corticosteroid (prednisolone ≥1mg/day) and/or immunosuppressant (cyclophosphamide, 
azathioprine, mycophenolate, cyclosporin) therapy. Treatment status was sub-categorised as “intention to 
treat” (treatment instituted within three months of presentation or continuation of pre-existing treatment) or 
“intention to observe” (the remaining patients on no therapy at three months of follow-up).  Trans-thoracic 
echocardiography and high resolution computed tomography (HRCT) of the chest were performed as 
previously reported (21). The presence of pulmonary hypertension (PHT) on echocardiography was defined 
as a pulmonary arterial systolic pressure of  ≥40mmHg (22). The UKRSA severity staging system, 
integrating disease extent on HRCT and forced vital capacity (FVC) levels, was used to sub-classify disease 
severity at presentation as “limited” or “extensive” (3) 
 
Pulmonary function data 
Standard pulmonary function tests (PFTs) (expressed as absolute values and percentage predicted) were 
 5 
performed (23), including a) forced vital capacity (FVC) levels, b) gas transfer (DLco) levels, c) gas transfer 
co-efficient (Kco) levels, d) the FVC/ DLco ratio. PFT measurements were obtained at a) baseline, b) 12 
months (range  9 to 18 months) from baseline, and c) 24 months (range  18 to 30 months) from baseline. 
Pulmonary function trends were analyzed as continuous and  categorical change in separate models. PFT 
change was computed as a percentage relative change from baseline absolute values, i.e.. a 10% relative 
decline in FVC equates to an FVC change from a baseline value  of 2.0 litres to 1.8 litres.  
 
Categorical PFT trends  at 12 months were defined as: a) FVC decline >10%; b) FVC decline >15%; c) 
DLco decline >15%; d)FVC decline >10% or DLco decline >15%; e) FVC decline >10% and DLco decline 
>15%; f) Kco decline >10% (why was the threshold of 10% chosen? Even if less variable than DLco, is 
there a reason for not looking at 15%?); g) FVC/DLco ratio rise >10%; h) FVC/DLco ratio rise >15%; i) 
FVC/DLco ratio rise > 20%.  Trends examined at 24 months consisted of a), c) and f)-i).  In addition, 
composite categorical decline (CCD), utilized in an IPF trial (24), was defined as either FVC decline >10% 
or FVC decline of 5 -9% in combination with a DLco decline >15%. 
Data analysis 
Analyses were performed using STATA software (Stata data analysis software; Computing Resource 
Centre, Santa Monica, CA). Data were expressed as means (SD) or medians (range), depending on 
distribution. Groups were compared using Student’s t test, Wilcoxon rank sum, chi-squared statistics and 
Fisher’s exact test, as appropriate. A p-value of <0.05 was considered significant. 15-year survival was 
examined using univariate proportional hazards analysis against baseline variables, change in individual 
PFTs at 12 months and change in individual PFTs at 24 months.   
 
Stepwise multivariate models were constructed in order to identify the determinants of mortality after 12 
months of follow-up and, separately, after 24 months of follow-up.  In both models, key covariates included 
baseline stage of interstitial lung disease (limited versus extensive disease), baseline severity of pulmonary 
vascular limitation (percent predicted Kco), progression of interstitial lung disease (categorical decline in 
FVC) and progression of pulmonary vascular limitation (categorical decline in Kco).  Other covariates 
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consisted of age, gender, treatment status (“intention to treat” versus “intention to observe”), smoking status 
and the presence or absence of pulmonary hypertension, as judged by echocardiography.   
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RESULTS 
Baseline data 
Demographic data and baseline pulmonary function tests are summarised in Table 1.   The cohort was 
characterised by a female predominance and the presence of “limited disease” in 70% of cases.   There were 
84 deaths (52%) during a median follow-up of 155 months.  There were no significant differences between 
the study cohort (n=162) and excluded patients (n=38) in gender (p=0.33), smoking status (p=0.57), baseline 
pulmonary function tests [FVC levels (p=0.77), DLco levels (p=0.32), Kco levels (p=0.55)] or survival 
(p=0.65). Patients in the excluded cohort were older  [mean age 53 years versus 48 years (p=0.03)].  
At baseline, FVC levels (hazards ratio [HR] = 0.98; 95% confidence intervals [CI] = 0.97, 1.00; p<0.01), 
DLco levels (HR = 0.96; 95% CI = 0.94, 0.97; p<0.0005), Kco levels (HR=0.97; 95% CI=0.96, 0.99; 
p<0.0005), FVC/DLco ratio (HR=2.73; 95% CI=1.79, 4.18; p<0.0005), disease stage (HR=3.01; 95% 
CI=1.90, 4.74; p<0.0005) and age (HR = 1.04; 95% CI = 1.02, 1.05; p<0.0005 ) were independent 
determinants of mortality, whereas gender and smoking status were not. 
 
Pulmonary function trends at 12 months and their prognostic significance: 
 
The prognostic significance of 12 month trends in FVC and DLco are shown in Table 2.  Continuous change 
in FVC and DLco was not predictive of outcome, with the exception of continuous FVC change in patients 
with extensive disease.  By contrast, categorical decline in FVC and/or DLco (using different thresholds) 
was predictive of mortality in all analyses in the whole cohort and in patients with extensive disease (see 
Figure 1 for FVC 10% change threshold data), although never predictive of mortality in patients with limited 
disease , regardless of threshold used (is this what you mean?) Categorical decline was most strongly 
predictive of mortality, both in whole cohort and in the extensive disease subgroup, when quantified as a) 
rise (why rise? Isn’t this the categorical decline category? Even if this is derived from a score which 
increases the greater the decline, may be worth explaining, as when you look at the figure, it seems it is the 
decline and therefore strange to speak of rise…)in the CCD (Figure 2); or b) decline in both FVC (>10%?) 
and/or DLco (>15%?), (found to be a relatively insensitive measure of decline) in the whole cohort, and this 
finding was replicated in patients with extensive disease (Table 2)  
Kco decline (analysed as continuous change and as a decline of 10% in separate models) and increases in the 
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FVC/DLco ratio (analysed as continuous change and as rises of 10%, 15% or 20% in separate models) were 
not predictive of mortality in the whole cohort, in limited disease or extensive disease (data not shown).  
 
In patients with extensive disease (and how about in the whole group?), the prognostic value of individual 
variables was unchanged when analysis was confined to patients in the “ intention to treat” sub-group 
(n=35): continuous change in FVC, p=0.03;   10% decline in FVC, p<0.01; a 15% decline in FVC, p<0.05; a 
10% decline in FVC and a 15% decline in DLco, p=0.04; rise in CCD, p<0.001. 
 
Multivariate analysis at 12 months 
On stepwise proportional hazards analysis of the whole cohort, the independent determinants of mortality 
were age (HR = 1.03; 95%CI = 1.01, 1.05; p<0.005), baseline stage of disease (HR = 2.30; 95%CI = 1.43, 
3.70; p<0.001), baseline Kco (HR = 0.98; 95%CI = 0.96, 0.99; p<0.005), rise in CCD at 12 months? (HR = 
2.25; 95%CI = 1.39, 3.63; p<0.001) and the (at baseline?) presence of pulmonary hypertension (HR = 2.05; 
95%CI = 1.07, 3.91; p=0.03) . and what about the decline in FVC > 10%, I imagine it does not hold ? 
Covariates discarded from the model consisted of gender, treatment status (“intention to treat” versus 
“intention to observe”, smoking status and decline in Kco >10%.   
 
Pulmonary function trends at 24 months and their prognostic significance: 
As shown in Table 3, prognostically significant pulmonary function trends in the whole cohort consisted of 
change in DLco (categorical decline, Fig3a), change in Kco (both continuous change and categorical 
decline, Fig3b) and change in the FVC/DLco ratio (categorical rise? by 15% and 20%, Fig3c). Changes in 
FVC and the CCD had no prognostic value.  Prognostically significant trends in patient severity sub-groups 
were confined to categorical changes in Kco and the FVC/DLco ratio in limited disease and change in the 
CCD in extensive disease.  
 
Analyses were repeated separately in the intention to treat (n=66) and intention to observe (n=74) sub-
groups.  A categorical decline in DLco of 15% was the only variable to have prognostic significance both in 
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the intention to treat sub-group (HR=2.06; 95% CI 1.03 to 4.12, p=0.04) and the intention to observe sub-
group (HR = 2.07, 95%CI 1.05 to 4.08, p=0.04).  A categorical decline in Kco of 10% remained significant 
in the intention to observe sub-group (p<0.005) but was only marginally significant in the intention to treat 
sub-group (p=0.11). 
 
Multivariate analysis at 24 months 
On stepwise proportional hazards analysis of the whole cohort, the independent determinants of mortality 
were  age? (HR = 1.04; 95%CI = 1.02, 1.06; p<0.0005), baseline stage of disease (HR = 2.54; 95%CI = 
1.52, 4.24; p<0.0005), baseline Kco (HR = 0.97; 95%CI = 0.95, 0.98; p<0.0005), decline in Kco >10% (HR 
= 2.88; 95%CI = 1.62, 5.10; p=0<0005)  and decline in FVC >10% (HR = 1.83; 95%CI = 1.07, 3.12; 
p=0.03). You don’t mention DLCO, does it not hold on multivariate? Covariates discarded from the model 
consisted of gender, treatment status (intention to treat versus  intention to observe), smoking status and 
pulmonary hypertension.  You don’t mention the multivariate of   extensive disease subgroup, but in the 
abstract you mention that CCD is the strongest determinant in this subgroup, does it hold on multivariate? 
 
Discussion 
 
We report that in an SSc-ILD cohort followed for over 15 years, pulmonary function trends at one and two 
years were predictive of intermediate to long-term mortality.  At one year, changes in FVC provided the 
most accurate prognostic information, with optimal expression of FVC change consisting of either a >10% 
decline in FVC from baseline or a marginal (5-9%) decline in FVC in association with a definite (i.e.>15%) 
decline in DLco.  The prognostic value of pulmonary function trends in the whole cohort was entirely 
ascribable to disease progression in patients with extensive SSSc-ILD.  At two years, serial gas transfer 
trends predicted survival much more accurately than FVC trends.   
 
Pulmonary function trends in the routine monitoring of SSc-ILD 
These findings support the view that the same broad approach to routine clinical monitoring is appropriate in 
SSc-ILD and in IPF.  In the 2011 international guideline for the diagnosis and management of IPF (16), the 
importance of monitoring both FVC and DLco was emphasized.  In the current cohort, categorical decline  
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in both variables at one year, both in isolation and in combination, were predictive of increased long-term 
mortality.  The fact that gas transfer trends at two years had much greater prognostic significance than FVC 
trends may seem surprising but this observation is consistent with the prognostic value of three year gas 
transfer trends in a previous smaller SSc-ILD cohort (25).  One possible explanation is that progression of 
SSc-ILD at two years may carry a greater threat to life expectancy when it has an impact on the pulmonary 
vasculature.  In principle, this might also apply to IPF but at present, the prognostic impact of two year 
pulmonary function trends in IPF is not known.  Importantly, a multivariate analysis of baseline data and 
pulmonary function trends at two years against subsequent survival established that baseline and serial 
variables relevant to both interstitial lung disease (i.e. baseline disease stage, CCD) and pulmonary vascular 
disease (i.e. baseline Kco, serial Kco) were all independently predictive of mortality, underlining the 
importance of continuing to monitor both FVC and DLco in the longer term. 
 
Implications for trial design: cohort enrichment       
The findings in the present study support a policy of “cohort enrichment” (i.e. selective recruitment of SSc-
ILD patients with extensive disease).  The growing consensus that SSc-ILD patients with mild lung 
involvement should not be recruited in treatment trials is based on the low prevalence of disease progression 
in that patient sub-group in the scleroderma lung study trial of oral cyclophosphamide (26) and also in the 
present cohort, although reported only as an integrated statement of “progression-free survival” in our earlier 
report and not analysed for individual variables (the preceding sentence not very clear) (3). The current 
findings present an additional argument for “cohort enrichment” for extensive disease in clinical trial 
recruitment: serial FVC trends (irrespective of the method of  quantification) had no long-term prognostic 
value in patients with limited disease and, thus, lack credibility as clinically relevant end-points in this 
patient sub-group.  Whilst the low prevalence of disease progression in limited disease was a contributing 
factor, the absence of marginally significant relationships between disease progression and mortality in 
patients with limited disease suggest that factors other than under-powering are likely to be at play.  One 
possible explanation is that when disease is limited, there is a higher prevalence of transient disease 
progression than in extensive disease and, therefore, short-term disease progression is less predictive of 
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longer-term disease behaviour than in extensive disease (in which, by definition, there is a “track record” of 
repeated disease progression).  It is also possible that in limited SSc-ILD, anti-inflammatory therapies 
(whether given for pulmonary or systemic indications) are more efficacious in stabilizing disease and, thus, 
more likely to confound linkages between short-term disease progression and long-term outcome. 
 
Implications for trial design: how should FVC change be expressed?       
Equally important with regard to study design was the observation that FVC change had no prognostic 
significance when quantified as a continuous variable.  This observation contrasts with findings in IPF (6) 
and calls into question extrapolation of current practice in IPF trials, in which the most frequent primary 
end-point is continuous change in FVC.  The less progressive nature of SSc-ILD, compared to IPF, may be 
the most important consideration.  It is generally accepted that in IPF, disease progression is the rule, 
although the rate of progression is variable and decline is interspersed with periods of stability.  By contrast, 
long term stabilization is seen in a significant proportion of SSc-ILD patients, even in extensive disease, and 
in other patients, progression is much more insidious than typically observed in IPF.  As a consequence, it 
appears likely that a greater proportion of continuous FVC change at one year in SSc-ILD is ascribable to 
measurement variation, compared to IPF, whereas  major FVC change captured by threshold analyses is 
much less likely to be spurious.    
 
The mode of expression of categorical change in FVC is a contentious area.  In clinical cohorts, a relative 
change of 10% from baseline has been shown to predict mortality in the majority of IPF studies (6;8;11-
13;15).  An absolute change in FVC of 10% of the predicted normal value also predicts mortality (7;9;27) 
but this larger amplitude of change is less prevalent than relative change in a given time period (28)).  In the 
current study, mortality was less strongly linked to a 10% decline in FVC than to a) a 15% decline in FVC; 
or b) both a 10% change in FVC and a 15% change in DLco.  However, the low prevalence of these 
alternative expressions of categorical decline mitigates against their use as trial end-points.  Our findings 
suggest that when the prevalence and the prognostic significance of decline are both taken into account, the 
optimal definition of categorical decline in FVC for trial purposes may consist of either a >10% decline in 
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FVC or a 5-9% “marginal” decline in FVC in association with a >15% decline in DLco.   The use of DLco 
trend data to indicate that marginal FVC change is likely to be clinically significant in individual patients 
(i.e. may represent an understatement of FVC change due to measurement variation in those cases) justifies 
amalgamation of trends in this way(29) and was the basis for an integrated FVC/DLco end-point in a recent 
IPF trial (24).  Our findings support a recent expert group recommendation for use of this end point in future 
SSc-ILD trials (30). 
 
Change in Kco versus change in the FVC/DLco ratio 
Our findings suggest that with regard to  monitoring, serial change in the FVC/DLco ratio is inferior to Kco 
trends.  In recent years, the FVC/DLco ratio has been advocated as a marker of pulmonary vasculopathy in 
systemic sclerosis (31-33).  However, the growth in use of this index can only be viewed as surprising.  The 
gas transfer coefficient (Kco)  (also known as “DLco/VA”) has been used for many decades to quantify 
uptake in carbon monoxide per unit of alveolar volume (VA).  Reduced Kco levels have an inverse 
correlation with the FVC/DLco ratio and both variables quantify reductions in DLco that are 
disproportionate to lung volumes.  However, Kco has the critically important advantage of the measurement 
variability of a single variable (measured Kco is used in combination with measured VA to compute DLco).  
By contrast, the FVC/DLco ratio has the measurement variability of three variables (FVC, VA and Kco).  
Substantially greater measurement variability is likely to explain the fact that a very large (20%) rise in the 
FVC/DLco ratio is required to provide the same prognostic guidance as a 10% decline in Kco.   
  
It should be stressed that in all prognostic evaluations of SSc-ILD cohorts, there are important but 
unavoidable confounding factors.  There is no current method of controlling definitively for treatment status 
as this often changes radically during both short-term and long-term follow-up.  We adopted a simplified 
approach to adjustment for treatment, as in previous work (3), cactegorising patients as being in “intention to 
observe” or “intention to treat” sub-groups, based on treatment decisions at presentation and during the first 
three months of follow-up.    Taking this dichotomy into account had no influence on our findings when 
included in multivariate modelling but this does not alter the fact that linkages between pulmonary function 
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change and mortality might have been much stronger had a robust method of adjusting for treatment effects 
been possible.  Similarly, a reliable means of distinguishing between respiratory and non-respiratory 
mortality might conceivably have strengthened our findings but in common with previous authors in this 
field, we viewed this distinction as highly unsafe, especially given the fact that very few deaths occurred at 
our institution. 
 
In summary, we have examined relationships between short term pulmonary function trends and long term 
outcome in interstitial lung disease associated with systemic sclerosis.  Disease severity at baseline and 
subsequent pulmonary function trends were independent prognostic determinants.  At one year, categorical 
FVC trends provide the most accurate prognostic information, especially when integrated with DLco trends.  
At two years, changes in gas transfer are more informative, with Kco trends more accurate prognostically 
than rises in the FVC/DLco ratio. 
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Table 1 
 
 
Age (years) 
Gender Male:Female 
Smoking status 
Survival 
Length of follow up (months) 
Disease stage 
“Intention to treat” at baseline 
Presence of PHT 
Pulmonary function: 
Baseline FEV1  
Baseline FVC  
Baseline DLco  
Baseline Kco 
Baseline FVC/DLco 
 
 
 
 
47.8 + 12.7 
29:133 
never=96, ex=53,current=13 
Alive = 78; Dead = 84 
154.6 (9.0 to 180.0) 
Limited = 113; Extensive =49 
limited disease 39/113;  extensive disease 35/49 
18/162 
 
78.5+ 18.3 (% predicted) 
79.6 + 21.1 (% predicted) 
56.2+ 16.6 (% predicted) 
78.0 + 16.2 (% predicted) 
1.48 + 0.42 
 
 
 
 
Definition of abbreviations: FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; 
DLco = gas transfer; PHT = pulmonary hypertension 
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Table 2 
    
Pulmonary function trends at 
12 months (prevalence of 
change stated for categorical 
thresholds) 
Prognostic significance 
in the whole cohort  
(n=162) 
Prognostic significance 
in limited disease 
(n= 113) 
Prognostic significance 
in extensive disease 
(n=49) 
Change in FVC stated as 
continuous data 
 
HR = 1.00 
95% CI = 0.98, 1.01 
p=0.56 
   
HR = 1.00 
95% CI = 0.99, 1.01 
p=0.56   
HR = 0.98 
95% CI = 0.95, 1.00 
p<0.05   
Decline in FVC >10%  
n=34, 21%: 
Limited disease 17/113, 15% 
Extensive disease 17/49, 35 % 
HR = 1.84  
95% CI = 1.14, 2.97 
p=0.01 
   
HR = 1.10 
95% CI = 0.52, 2.33 
p=0.81  
HR = 2.31 
95% CI = 1.16, 4.60 
P=0.02 
Decline in FVC >15%  
(n=20, 12%) 
Limited disease 7/113, 6% 
Extensive disease 13/49, 27% 
HR = 2.36;  
95% CI = 1.35, 4.14 
P<0.005 
   
HR = 1.05 
95% CI = 0.33, 3.37 
p=0.94   
HR = 2.32 
95% CI = 1.14, 4.73 
p=0.02   
Change in Dlco stated as 
continuous data 
 
HR =1.00;  
95% CI = 0.99, 1.01 
P=0.68 
   
HR = 1.00 
95% CI = 0.99, 1.01 
p=0.57 
HR = 0.98 
95% CI = 0.96,1.00 
P=0.12   
Decline in DLco >15%  
(n=36, 22%) 
Limited disease 16/113, 14% 
Extensive disease 20/48, 42% 
HR = 1.84  
95% CI = 1.15, 2.95 
p=0.01 
   
HR = 1.23 
95% CI = 0.60, 2.53 
p=0.57   
HR = 1.89 
95% CI = 0.94, 3.78 
p=0.07   
Decline in FVC >10% AND 
Dlco >15% 
(n=18, 11%) 
Limited disease  7 /113, 6% 
Extensive disease  11/48, 23% 
 
HR = 2.40 
95% CI = 1.35, 4.26 
P<0.005 
HR = 0.91 
95% CI = 0.28, 2.93 
p=0.88 
HR = 3.14 
95% CI = 1.51, 6.54 
P<0.005 
Decline in FVC >10% OR 
Dlco >15% 
(n=51, 32%) 
Limited disease 26 /113, 23%  
Extensive disease  25 /48, 52% 
HR = 1.69 
95% CI = 1.09, 2.62 
p=0.02 
HR = 1.27 
95% CI = 0.69, 2.36 
p=0.44 
HR = 1.68 
95% CI = 0.83, 3.40 
p=0.15 
CCD 
(n=42, 26%) 
Limited disease 22/113, 19% 
Extensive disease 20/49 41% 
HR = 1.96  
95% CI = 1.25, 3.08 
P<0.005 
   
HR = 1.17 
95% CI = 0.60, 2.27 
p=0.65   
HR = 2.86 
95% CI = 1.44, 5.71 
P<0.005   
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Table 3 
 
Pulmonary function trends at 
24 months (prevalence of 
change stated for categorical 
thresholds) 
Prognostic significance 
in the whole cohort  
(n=140) 
Prognostic significance 
in limited disease 
(n= 100) 
Prognostic significance 
in extensive disease 
(n=40) 
Change in FVC stated as 
continuous data 
 
HR = 1.00 
95% CI = 0.99, 1.01 
p=0.88 
   
HR = 1.00 
95% CI = 1.00, 1.01 
p=0.34   
HR = 0.98 
95% CI = 0.96, 1.00 
p=0.07   
Decline in FVC >10%  
(n=42, 30%) 
Limited disease 30/100, 30% 
Extensive disease 12/40, 30% 
HR = 1.25  
95% CI = 0.77, 2.04 
p=0.37 
   
HR = 1.10 
95% CI = 0.58, 2.05 
p=0.79  
HR = 1.68 
95% CI = 0.77, 3.68 
p=0.20 
Decline in FVC >12%  
(n=35, 25%) 
Limited disease 23/100, 23% 
Extensive disease 12/40, 30% 
HR = 1.28  
95% CI = 0.77, 2.15 
p=0.35 
   
HR = 0.99 
95% CI = 0.49, 2.01 
p=0.99   
HR = 1.68 
95% CI = 0.77, 3.68 
p=0.20   
Decline in FVC >15%  
(n=27, 19%) 
Limited disease 16/100, 16% 
Extensive disease 11/40, 28% 
HR = 1.08  
95% CI = 0.60, 1.93 
p=0.80 
   
HR = 0.62 
95% CI = 0.24, 1.57 
p=0.32   
HR = 1.45 
95% CI = 0.65, 3.23 
p=0.37   
Change in Dlco stated as 
continuous data 
 
HR = 1.00  
95% CI = 0.99, 1.01 
p=0.85 
   
HR = 1.00 
95% CI = 0.99, 1.01 
p=0.46 
HR = 0.99 
95% CI = 0.96, 1.01 
p=0.19   
Decline in DLco >15%  
(n=39, 28%) 
Limited disease 20/100, 20% 
Extensive disease 19/39, 49% 
HR = 2.03  
95% CI = 1.25, 3.29 
p<0.005 
   
HR = 1.47 
95% CI = 0.75, 2.91 
p=0.26   
HR = 2.16 
95% CI = 0.99, 4.73 
p=0.05   
Change in Kco stated as 
continuous data 
 
HR = 0.98  
95% CI = 0.96, 1.00 
p=0.04 
   
HR = 0.98 
95% CI = 0.95, 1.00 
p=0.09   
HR = 0.99 
95% CI = 0.97, 1.01 
p=0.31   
Decline in Kco >10%  
(n=27, 19%) 
Limited disease 15/100, 15% 
Extensive disease 12/39, 31% 
HR = 2.35  
95% CI = 1.40, 3.95 
p<0.001 
   
HR = 2.57 
95% CI = 1.30, 5.09 
p<0.01   
HR = 1.67 
95% CI = 0.74, 3.75 
p=0.22   
Change in the FVC/DLco ratio 
stated as continuous data 
 
HR = 1.01  
95% CI = 0.99, 1.03 
p=0.26 
   
HR = 1.01 
95% CI = 0.99, 1.03 
p=0.38   
HR = 1.00 
95% CI = 0.98, 1.02 
p=0.79   
Increase in FVC/DLco >10%  
(n=47, 36%) 
Limited disease 29/100, 29% 
Extensive disease 18/39, 46% 
HR =  1.19 
95% CI = 0.73, 1.94 
p=0.50 
   
HR = 1.34 
95% CI = 0.71, 2.52 
p=0.37   
HR = 0.79 
95% CI = 0.35, 1.75 
p=0.56   
Increase in FVC/DLco >15%  
(n=30, 22%) 
Limited disease 17/100, 17% 
Extensive disease 13/39, 33% 
HR = 2.06  
95% CI = 1.19, 3.37 
p<0.01 
   
HR = 2.12 
95% CI = 1.07, 4.22 
p=0.03   
HR = 1.53 
95% CI = 0.68, 3.46 
p=0.30   
Increase in FVC/DLco >20%  
(n=23, 17%) 
Limited disease 12/100, 12% 
Extensive disease 11/39, 28% 
HR = 2.45  
95% CI = 1.41, 4.23 
p<0.001 
   
HR = 2.70 
95% CI = 1.29, 5.63 
p<0.01   
HR = 1.66 
95% CI = 0.72, 3.86 
p=0.24   
CCD 
(n=48, 35%) 
Limited disease 33/100, 33% 
Extensive disease 15/39 38% 
HR = 1.43  
95% CI = 0.89, 2.30 
p=0.14 
   
HR = 1.06 
95% CI = 0.57, 1.97 
p=0.86   
HR = 2.52 
95% CI = 1.16, 5.49 
p=0.02   
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Table legends: 
 
Table 1: Demographic and clinical data in the study population (n=162) 
 
Table 2: The prevalence of categorical change and relationships between 12 month changes in pulmonary 
function variables (FVC, DLco, Kco, the FVC/DLco ratio, the CCD) and mortality in the whole cohort and, 
separately, in the limited and extensive disease sub-groups.  Pulmonary function trends are expressed as 
continuous data or as categorical change to pre-defined thresholds (with prevalence stated in parentheses).  
Prognostic significance is expressed as hazards ratios (HR) with 95% confidence intervals (CI) and p values. 
 
Table 3: The prevalence of categorical change and the relationships between 24 month changes in 
pulmonary function variables (FVC, DLco, Kco, the FVC/DLco ratio, the CCD) and mortality in the whole 
cohort and, separately, in the limited and extensive disease sub-groups.  Pulmonary function trends are 
expressed as continuous data or as categorical change to pre-defined thresholds (with prevalence stated in 
parentheses).  Prognostic significance is expressed as hazards ratios (HR) with 95% confidence intervals 
(CI) and p values. 
 
Figure legends: 
 
Figure 1: FVC decline at 10% threshold at 12 months is predictive of mortality in a) the whole cohort 
(n=162) (HR=1.84; 95% CI 1.14, 2.97; p=0.01); b) the extensive subgroup (n=49) (HR=2.31; CI 1.16, 4.6; 
p=0.02) 
 
Figure 2: CCD at 12 months is predictive of mortality in a) the whole cohort (n=162) (HR=1.96; CI 1.25, 
3.08; p<0.005) ; b) the extensive subgroup (n=49) (HR=2.86; CI 1.44, 5.71; p<0.005) 
 
 
Figure 3: The prognostic significance of PFT trends at different thresholds at 24 months in the whole cohort 
(n=113)): a) DLco decline at 15% threshold (HR=2.03, 95% CI 1.25, 3.3, p<0.005); b) Kco decline at 10% 
threshold (HR=2.35, 95% CI 1.40, 3.95; p<0.001); and c) FVC/DLco ratio rise at 20% threshold (HR=2.45, 
95% CI 1.41, 4.23, p<0.001). 
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Figure 1.  
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Figure 2.  
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 Figure 3.  
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